What is Certara, Inc.'s P/E and P/B ratio?

Certara, Inc. has a P/E ratio of -72.1 and a P/B ratio of 1.59.

What is Certara, Inc.'s debt-to-equity ratio?

Certara, Inc. has a debt-to-equity ratio of 0.31.

How much does Certara, Inc. owe compared with what it owns?

Certara, Inc. owes $0.31 for every $1 it owns (balance sheet Jun 2026), which is low.

Does Certara, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Certara, Inc..

Where can I read the latest news about Certara, Inc.?

Recent headlines about Certara, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Certara, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Certara, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

Certara, Inc. (CERT) Stock Price Analysis

Q: What is Certara, Inc.'s Positivity rank?

Certara, Inc. is ranked #4,733 of 6,767 companies globally and #2,451 of 4,000 in United States on PositoAI, with a Positivity Score of 19,030.

Certara, Inc. — Overview & Financial Snapshot

Certara, Inc. (NasdaqGS: CERT) is a Healthcare company, ranked #4,733 of 6,767 companies globally and #2,451 of 4,000 in United States on PositoAI, with a Positivity Score of 19,030. Its market capitalisation is ₹14,527.85 Cr ($1.54B), P/E ratio is -72.1 and P/B ratio is 1.59. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Powered by OpenAI

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Certara, Inc.